Evidence map›Paper›PMID 39641569›Full record

ArticleAntimicrobial agents and chemotherapy2025

Characterization and genomic analysis of the highly virulent

Zhien He, Yi Huang, Wei Li, Huanhuan Zhang, Ruobing Cao, Md Roushan Ali, Yuanyuan Dai, Huaiwei Lu, Wanying Wang, Qiuhong Niu and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Antimicrobial agents and chemotherapy · 2025
    Review
  3. Article
  4. Recent advances in host models in studying virulence factors and pathogenesis ofFrontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zhien HeDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0003-4679-7839
Yi HuangDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Wei LiDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Huanhuan ZhangDepartment of Cancer Epigenetics Program, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China.
Ruobing CaoDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Md Roushan AliDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0002-8894-2566
Yuanyuan DaiDepartment of Clinical Laboratory, the First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Huaiwei LuDepartment of Clinical Laboratory, the First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Wanying WangDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Qiuhong NiuSchool of Life Science, Nanyang Normal University, Nanyang, Henan, China.
Baolin SunDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0002-2896-3015
Yujie LiDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.ORCID 0000-0001-9293-6233

Funding

Foundation of the west branch of the First Affiliated Hospital of University of Science and Technology of China 2022YJQN024Fundamental Research Funds for the Central Universities WK9100000080National Key Research and Development Program of China 2021YFC2300300National Natural Science Foundation of China 32070132Natural Science Foundation of Anhui Province, China 2408085MC061USTC Research Funds of the Double First-Class Initiative YD9100002063
6 · The paper itself

Abstract

The multidrug-resistant

Indexed as

Acinetobacter baumanniiAcinetobacter InfectionsAnimalsAnti-Bacterial AgentsChinaDrug Resistance, Multiple, BacterialGenome, BacterialHumansMicrobial Sensitivity TestsMothsPolymorphism, Single NucleotideVirulenceWhole Genome SequencingAnti-Bacterial AgentsAcinetobacter baumanniiCC92ST1791whole genome sequencing

Identifiers

PMID39641569
PMCPMC11784083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.